Morisada Hayakawa

Morisada Hayakawa

Auto-generated profile, based on publicly available information

Morisada Hayakawa

Department of Biochemistry, Jichi Medical University School of Medicine, Tochigi, Japan

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2007 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
HHHiroko Hayakawa
Hiroko Hayakawa
MHMorisada Hayakawa
Morisada Hayakawa
AKAkihiro Kume
Akihiro Kume
STShin-Ichi Tominaga
Shin-Ichi Tominaga
The ST2 gene produces a soluble secreted form and a transmembrane form, referred to as soluble ST2 and ST2L, respectively. A recent study has reported that interleukin (IL)-33 is a specific ligand of ST2L and induces production of T helper type 2 (Th2) cytokines. Although soluble ST2 is highly produced in sera of asthmatic patients and plays a critical role for production of Th2 cytokines, the function of soluble ST2 in relation to IL-33 signaling remains unclear. Here we show antagonistic effects of soluble ST2 on IL-33 signaling using a murine thymoma EL-4 cells stably expressing ST2L and a murine model of asthma. Soluble ST2 directly bound to IL-33 and suppressed activation of NF-κB in EL-4 cells stably expressing ST2L, suggesting that the complex of soluble ST2 and IL-33 fails to bind to ST2L. In a murine model of asthma, pretreatment with soluble ST2 reduced production of IL-4, IL-5, and IL-13 from IL-33-stimulated splenocytes. These results indicate that soluble ST2 acts as a negative regulator of Th2 cytokine production by the IL-33 signaling. Our study provides a molecular mechanism wherein soluble ST2 modulates the biological activity of IL-33 in allergic airway inflammation.

16 November 2009 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
YMYasushi Matsuyama
Yasushi Matsuyama
HOHitoaki Okazaki
Hitoaki Okazaki
HTHiroyuki Tamemoto
Hiroyuki Tamemoto
HKHirotaka Kimura
Hirotaka Kimura
YKYasuyuki Kamata
Yasuyuki Kamata
SMSeiji Minota
Seiji Minota
Objective. To determine levels of interleukin 33 (IL-33) in serum and synovial fluid (SF) and their clinical associations in patients with rheumatoid arthritis (RA). To evaluate the ability of activated peripheral blood mononuclear cells (PBMC) and fibroblast-like synoviocytes (FLS) from RA patients to release IL-33.

1 September 2008 in Cellular Signalling
Verified
Journal Article
Closed access
MFMegumi Funakoshi-Tago
Megumi Funakoshi-Tago
KTKenji Tago
Kenji Tago
MHMorisada Hayakawa
Morisada Hayakawa
STShin-Ichi Tominaga
Shin-Ichi Tominaga
TOTomoyuki Ohshio
Tomoyuki Ohshio
TKTadashi Kasahara
Tadashi Kasahara

1 August 2001 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
KTKenji Tagoa
Kenji Tagoa
TNTakahiro Nodab
Takahiro Nodab
MHMorisada Hayakawaa
Morisada Hayakawaa
HIHiroyuki Iwahanaa
Hiroyuki Iwahanaa
KYKen Yanagisawaa
Ken Yanagisawaa
STShin-Ichi Tominaga
Shin-Ichi Tominaga

12 September 2009 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
SAShinsuke Aoki
Shinsuke Aoki
MHMorisada Hayakawa
Morisada Hayakawa
HOHiromi Ozaki
Hiromi Ozaki
NTNaoki Takezako
Naoki Takezako
HOHiroto Obata
Hiroto Obata
KYKen Yanagisawa
Ken Yanagisawa

1 September 2009 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
MHMorisada Hayakawa
Morisada Hayakawa
HHHiroko Hayakawa
Hiroko Hayakawa
YMYasushi Matsuyama
Yasushi Matsuyama
HTHiroyuki Tamemoto
Hiroyuki Tamemoto
HOHitoaki Okazaki
Hitoaki Okazaki
STShin-Ichi Tominaga
Shin-Ichi Tominaga